sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib teva 50 mg tvrdé kapsuly
teva b.v., holandsko - sunitinib - 44 - cytostatica
sunitinib teva 25 mg tvrdé kapsuly
teva b.v., holandsko - sunitinib - 44 - cytostatica
sunitinib teva 12,5 mg tvrdé kapsuly
teva b.v., holandsko - sunitinib - 44 - cytostatica
sunitinib stada 50 mg
stada arzneimittel ag, nemecko - sunitinib - 44 - cytostatica
sunitinib stada 25 mg
stada arzneimittel ag, nemecko - sunitinib - 44 - cytostatica
sunitinib stada 12,5 mg
stada arzneimittel ag, nemecko - sunitinib - 44 - cytostatica
sunitinib sandoz 50 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica
sunitinib sandoz 25 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica
sunitinib sandoz 12,5 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica